Logo

Novartis Signs a License and Collaboration Agreement with Cellular Biomedicine Group (CBMG) for CAR-T Cell Therapy in China

Share this

Novartis Signs a License and Collaboration Agreement with Cellular Biomedicine Group (CBMG) for CAR-T Cell Therapy in China

Shots:

  • Novartis to get royalty-free worldwide- intellectual property rights for CBMG’s CAR-T related technology. CBMG to get a mark-up on the manufacturing cost. CBMG will take care of the manufacturing process- and Novartis will undertake distribution- regulatory and commercialization in China
  • Novartis to pay $40M in the form of equity purchase for its 1-458-257 shares at $27.43/share) ~9% of CBMG and also pay single-digit milestone payment to CBMG. Under the agreement the CBMG will manufacture and supply CAR-T cell therapy Kymriah (tisagenlecleucel) in China- and Novartis will have the commercialization rights
  • The agreement will focus on bringing CAR-T cell therapy Kymriah in China- currently approved in the US- EU and Canada for treatment of cancer

Ref: Cellular Biomedicine Group | Image: NAI500

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions